Drugs & Aging

, Volume 1, Issue 3, pp 194–211 | Cite as

Antihypertensive Therapy in the Aged Patient

Clinical Pharmacokinetic Considerations
  • Robert W. Piepho
  • Kermit J. Fendler
Review Article Clinical Pharmacology

Summary

The incidence of both systolic and diastolic hypertension is increased in elderly patients, therefore antihypertensive drugs are commonly used in this population. In addition to changes in blood pressure, the aging process also causes numerous changes in other physiological parameters, resulting in altered pharmacokinetic and pharmacodynamic responses to the drugs.

The dosage regimens for thiazide diuretics and amiloride must be individually titrated in the elderly patient, since the elimination of these agents decreases concurrently with decreased renal function, as indicated by compromised creatinine clearance. The initial doses of the calcium antagonists should be decreased in elderly patients, since representative compounds from all 3 chemically heterogeneous classes have been shown to have decreased clearance in these patients which appears to be primarily due to the status of hepatic function in the patient. However, with verapamil, the dosage should be further decreased in association with compromised renal function.

The dosage of the angiotensin converting enzyme (ACE) inhibitors should be adjusted according to renal function rather than age. Lisinopril, which is primarily eliminated unchanged, is usually given in lower doses in the elderly, and doses of both captopril and enalapril may need to be reduced, depending on renal function. While there is no need to adjust the dosage regimen for the α-adrenoceptor blocking drugs (prazosin, terazosin), caution should be used with the β-adrenergic blockers, particularly the hydrophilic agents, since they are renally eliminated. Labetalol may be a suitable alternative β-blocker for the elderly patient, since its pharmacodynamic properties of decreased systemic vascular resistance without changes in heart rate or stroke volume are preferential for the elderly patient, and its pharmacokinetics are relatively unchanged in this population.

Drugs that act primarily through the central nervous system, such as clonidine, methyldopa and guanfacine, require smaller doses in the presence of renal dysfunction. In contrast, guanabenz is metabolised primarily by the liver, so it would appear to be useful in elderly patients with renal dysfunction despite the lack of studies in this population. Guanadrel, an adrenergic neuron blocking drug, also requires a dosage reduction in patients with impaired renal function.

In addition to the pharmacokinetic changes that occur in the elderly patient, pharmacodynamic changes may also be anticipated due to receptor modifications. Older patients have a decrease in β-receptor sensitivity, while α-receptor sensitivity does not change. When designing the dosage regimen for a senior patient with hypertension, the combination of all these variables must be considered.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abernethy DR. The pharmacokinetic profile of amlodipine. American Heart Journal 118: 1100–1103, 1989PubMedCrossRefGoogle Scholar
  2. Abernethy DR, Montamat SC. Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. American Journal of Cardiology 60: 1161–1201, 1987CrossRefGoogle Scholar
  3. Abernethy DR, Schwartz JB, Placehetka JR, Todd EL, Egan JM. Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. American Journal of Cardiology 60: 697–702, 1987PubMedCrossRefGoogle Scholar
  4. Abernethy DR, Schwartz JB, Todd EL, Luchi R, Snow E. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients: altered electrocardiographic and hypotensive responses. Annals of Internal Medicine 105: 329–336, 1986PubMedGoogle Scholar
  5. Allegraud P. Hypertension arterielle du sujet age: emploi d’un beta-bloquant, le Visken, dans 30 cas. Medecine Praticienne 695: 112–114, 1978Google Scholar
  6. Amery A, Birkenhager W, Brixko W, Bulpitt C, Clement D, et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over the age of sixty. Lancet 2: 589–592, 1986PubMedCrossRefGoogle Scholar
  7. Anderson KV, Bretell HR, Aikawa JK. Carbon 14-labelled hydrochlorothiazide in human beings. Archives of Internal Medicine 107: 736–742, 1961PubMedCrossRefGoogle Scholar
  8. Applegate WB. Hypertension in elderly patients. Annals of Internal Medicine 110: 901–915, 1989PubMedGoogle Scholar
  9. Australian National Blood Pressure Study Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1: 1261–1267, 1980Google Scholar
  10. Baksi A, Edwards JS. Pharmacokinetics of nitrendipine in the elderly. Journal of Cardiovascular Pharmacology 14 (Suppl. 10): S33–S35, 1989PubMedGoogle Scholar
  11. Baldwin T, Vacek J. Use of cardiovascular drugs in the elderly: what difference does age make? Postgraduate Medicine 85: 319–330, 1989PubMedGoogle Scholar
  12. Bandar AD. Pharmacologic aspects of aging: a survey of the effects of increasing age on drug activity in adults. Journal of the American Geriatric Society 12: 114–134, 1964Google Scholar
  13. Beerman B. Pharmacokinetics of lisinopril. American Journal of Medicine 85 (Suppl. 3B) 25–30, 1988CrossRefGoogle Scholar
  14. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. European Journal of Clinical Pharmacology 5: 297–303, 1977CrossRefGoogle Scholar
  15. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. British Journal of Clinical Pharmacology 7: 579–583, 1979PubMedCrossRefGoogle Scholar
  16. Beermann B, Groschinsky-Grind M, Rosen A. Absorption, metabolism and excretion of carbon 14-hydrochlorothiazide. Clinical Pharmacology and Therapeutics 19: 531–537, 1976PubMedGoogle Scholar
  17. Beresford R, Heel RC. Betaxolol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. Drugs 31: 6–28, 1986PubMedCrossRefGoogle Scholar
  18. Bertel O, Marx BE, Conen D, Effects of antihypertensive treatment on cerebral perfusion. American Journal of Medicine 82 (Suppl 3B): 29–36, 1987PubMedCrossRefGoogle Scholar
  19. Birkenhäger WH, Choosing the optimum therapy for older hypertensive patients. Drugs & Aging 1: 36–47, 1991CrossRefGoogle Scholar
  20. Bortel LV, Bohm R, Mooij J, Schiffers P, Rahn KH. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. European Journal of Clinical Pharmacology 37: 185–189, 1989PubMedCrossRefGoogle Scholar
  21. Buhler FR. Antihypertensive treatment according to age, plasma renin and race. Drugs 35: 495–503, 1988PubMedCrossRefGoogle Scholar
  22. Buhs RP, Beck JL, Speth OC, Smith JL, Trenner NR, et al. The metabolism of methyldopa in hypertensive human subjects. Journal of Pharmacology and Experimental Therapeutics 143: 205–214, 1964PubMedGoogle Scholar
  23. Cannon PJ, Whitlock RT, Morris C, Angers M, Laragh JH. Effect of alpha-methyldopa in severe and malignant hypertension. Journal of the American Medical Association 179: 673–681, 1962PubMedCrossRefGoogle Scholar
  24. Carchman SH, Sica DA, Davis J, Crowe JT, Wasserman AJ, et al. Steady-state plasma levels and pharmacokinetics of guanfacine in patients with renal insufficiency. Nephron 53: 18–23, 1989PubMedCrossRefGoogle Scholar
  25. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. British Journal of Clinical Pharmacology 7: 49–54, 1979PubMedCrossRefGoogle Scholar
  26. Castleden CM, Kaye CM, Parson RL. The effect of age on plasma levels of propranolol and practolol in man. British Journal of Clinical Pharmacology 2: 303–306, 1975PubMedCrossRefGoogle Scholar
  27. Challenor VF, Waller DG, Renwick AG, Gruchy BS, George CF. The trans-hepatic extraction of nifedipine. British Journal of Clinical Pharmacology 24: 473–477, 1987PubMedCrossRefGoogle Scholar
  28. Chaudhry AY, Bing RF, Castleden CM, Swales JD, Napier CJ. The effect of aging on the response to frusemide in normal subjects. European Journal of Clinical Pharmacology 27: 303–306, 1984PubMedCrossRefGoogle Scholar
  29. Chobanian AV. Treatment of the elderly hypertensive patient. American Journal of Medicine 77: 22–27, 1984PubMedGoogle Scholar
  30. Cirillo VJ, Till AE, Gomez HJ, Shi WJ, Thien G. Effect of age on lisinopril pharmacokinetics. Abstract. Clinical Pharmacology and Therapeutics 39: 187, 1986Google Scholar
  31. Davies DS, Wing LMH, Reid JL, Neill E, Tippett P, et al. Pharmacokinetics and concentration effect relationships of intravenous and oral clonidine. Clinical Pharmacology and Therapeutics 21: 593–601, 1977PubMedGoogle Scholar
  32. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clinical Pharmacokinetics 17: 236–263, 1989PubMedCrossRefGoogle Scholar
  33. Dollery CI, Harrington M. Methyldopa in hypertension. Lancet 1: 759–763, 1962PubMedCrossRefGoogle Scholar
  34. Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular disease. Clinical Pharmacokinetics 14: 241–259, 1988PubMedCrossRefGoogle Scholar
  35. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clinical Pharmacokinetics 11: 425–449, 1986PubMedCrossRefGoogle Scholar
  36. Elliott HL, Meredith PA, Vincent J, Reid JL. Clinical pharmacological studies with doxazosin. British Journal of Clinical Pharmacology 21: 27S–31S, 1986PubMedCrossRefGoogle Scholar
  37. Emeriau J-P. Guidelines for treating hypertension in the elderly. Drugs 38: 612–620, 1989PubMedCrossRefGoogle Scholar
  38. Forette F, Bellet M, Henry JF, Hervy MP, Poyard-Salmeron C, et al. Effect of nicardipine in elderly hypertensive patients. British Journal of Clinical Pharmacology 20: 125S–129S, 1985PubMedCrossRefGoogle Scholar
  39. Freis ED. Age and antihypertensive drugs (hydrochlorbthiazide; bendroflumethiazide, nadolol and captopril). American Journal of Cardiology 61: 117–121, 1988PubMedCrossRefGoogle Scholar
  40. Frishman WH. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. New England Journal of Medicine 308(16): 940–944, 1983PubMedCrossRefGoogle Scholar
  41. Frishman WH, Charlap S, Michelson EL. Calcium channel blockers in systemic hypertension. American Journal of Cardiology 58: 157–160, 1986PubMedCrossRefGoogle Scholar
  42. Frisk-Holmberg M, Edlund PO, Paalzow L. Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients. British Journal of Clinical Pharmacology 6: 227–232, 1978PubMedCrossRefGoogle Scholar
  43. Gautam PC, Vargas E, Lye M. Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure. Journal of Pharmacy and Pharmacology 39: 929–931, 1987PubMedCrossRefGoogle Scholar
  44. George CF. Amiloride handling in renal failure. British Journal of Clinical Pharmacology 9: 94–95, 1980PubMedCrossRefGoogle Scholar
  45. Gifford RW. Isolated systolic hypertension in the elderly: some controversial issues. Journal of the American Medical Association 247: 781–785, 1982PubMedCrossRefGoogle Scholar
  46. Gifford RW. Management of isolated systolic hypertension in the elderly. Journal of the American Geriatrics Society 34: 106–111, 1986PubMedGoogle Scholar
  47. Giuntoli F, Gabbani S, Natali A, Galeone F, Saba P, et al. Captopril in elderly hypertensive patients: efficacy and tolerability in a long term study. Current Therapeutic Research 45: 1025–1030, 1989Google Scholar
  48. Gray DR, Weber MA, Drayer JIM. Effects of low-dose antihypertensive therapy in elderly patients with predominant systolic hypertension. Journal of Gerontology 38: 302–306, 1983PubMedGoogle Scholar
  49. Greenblatt DJ. Disposition of cardiovascular drugs in the elderly. Medical Clinics of North America 73: 487–494, 1989PubMedGoogle Scholar
  50. Gretzer I, Alvan G, Duner H, Garle M, Sjoqvist F. Beta-blocking effect and pharmacokinetics of pindolol in young and elderly hypertensive patients. European Journal of Clinical Pharmacology 31: 415–418, 1986PubMedCrossRefGoogle Scholar
  51. Hanson A, Johansson BW, Wernersson B, Wahlander LA. Pharmacokinetics of oral hydralazine in chronic heart failure. European Journal of Clinical Pharmacology 25: 467–473, 1983PubMedCrossRefGoogle Scholar
  52. Herrera J, Vukovich RA, Griffith DL. Elimination of nadolol by patients with renal impairment. British Journal of Clinical Pharmacology 7 (Suppl. 2): 227S–231S, 1979PubMedCrossRefGoogle Scholar
  53. Hitzenberger G, Fitscha P, Beveridge T, Nuesch E, Pacha W. Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. British Journal of Clinical Pharmacology 13: 217S–222S, 1982PubMedCrossRefGoogle Scholar
  54. Ho PC, Triggs EJ. Drug therapy in the elderly. Australian and New Zealand Journal of Medicine 14: 179–190, 1984PubMedCrossRefGoogle Scholar
  55. Hockings N, Ajayi AA, Reid JL. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprit. British Journal of Clinical Pharmacology 21: 341–348, 1986PubMedCrossRefGoogle Scholar
  56. Houston MC. New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. American Heart Journal 117: 911–951, 1989PubMedCrossRefGoogle Scholar
  57. Hulley SB, Furberg CD, Gurland B. Systolic hypertension in the elderly program (SHEP): antihypertensive efficacy of chlorthalidone. American Journal of Cardiology 56: 913–920, 1985PubMedCrossRefGoogle Scholar
  58. Hulter HN, Licht JH, Flnicki LP, Singh S. Clinical efficacy and pharmacokinetics of clonidine in hemodialysis in renal insufficiency. Journal of Laboratory and Clinical Medicine 94: 223–231, 1979PubMedGoogle Scholar
  59. Hypertension Detection and Follow Up Program Cooperative Group. Five year findings of the hypertension detection and follow up program: mortality by race, sex and age. Journal of the American Medical Association 242: 2572–2577, 1979CrossRefGoogle Scholar
  60. Ishizaki T, Hirayama H, Tawara K, Nakaya H, Sato M, et al. Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug. Journal of Pharmacology and Experimental Therapeutics 212(1): 173–181, 1980PubMedGoogle Scholar
  61. Jenkins AC, Knill JR, Dreslinski GR. Captopril in the treatment of elderly hypertensive patients. Archives of Internal Medicine 145: 2020–2031, 1985CrossRefGoogle Scholar
  62. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The 1988 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Archives of Internal Medicine 148: 1023–1038, 1988CrossRefGoogle Scholar
  63. Jungers P, Ganeval D, Pertuiset N, Schauveau P. Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. American Journal of Medicine 80 (Suppl. 5b) 94–99, 1986PubMedCrossRefGoogle Scholar
  64. Kannel WB, Gordon T. Cardiovascular risk factors in the aged: the Framingham Study in Epidemiology of Aging. NIH Publication No. 80 969, pp. 65–89, National Institute of Aging Bethesda, MD 1980Google Scholar
  65. Kelly J, McGarry K, O’Malley K, O’Brien ET. Bioavailability of labetolol increases with age. British Journal of Clinical Pharmacology 14: 304–305, 1982PubMedCrossRefGoogle Scholar
  66. Kendall MJ, Quarterman CP. The effect of age on the pharmacokinetics of oxprenolol. International Journal of Clinical Pharmacology, Therapeutics and Toxicology 20(3): 101–104, 1982Google Scholar
  67. Klein C, Gerber JC, Payne NA, Nies AS. The effect of age on the sensitivity of the α1-adrenoceptor to phenylephrine and prazosin. Journal of Clinical Pharmacology and Therapeutics 47: 535–539, 1990CrossRefGoogle Scholar
  68. Klein C, Morton N, Kelley S, Metz S. Transdermal clonidine therapy in elderly mild hypertensives: effects on blood pressure, plasma norepinephrine and fasting plasma glucose. Journal of Hypertension 3: S81–S84, 1985PubMedCrossRefGoogle Scholar
  69. Kleinbloesem CH, vanBrummelen P, Breimer DD. Nifedipine relationship between pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics 12: 12–29, 1987PubMedCrossRefGoogle Scholar
  70. Knauf H, Mohrke W, Mutschier E. Delayed elimination of triamterene and its active metabolite in chronic renal failure. European Journal of Clinical Pharmacology 24: 453–456, 1983PubMedCrossRefGoogle Scholar
  71. Kobinger W, Walland A. Circulation studies with two-(2,6-di-chlorophenylamino)-2-imidazoline hydrochloride. Arzneimittel-Forschung 17: 292–300, 1967PubMedGoogle Scholar
  72. Koch G. Hemodynamic changes after acute and long-term combined alpha-beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade. Journal of Cardiovascular Pharmacology 3 (Suppl. 1): S30–S41, 1981PubMedCrossRefGoogle Scholar
  73. Lam YWF, Shepherd AMM. Drug interactions in hypertensive patients: pharmacokinetic, pharmacodynamic and genetic considerations. Clinical Pharmacokinetics 18(4): 295–317, 1990PubMedCrossRefGoogle Scholar
  74. Lawson DH, Gloss D, Jick J. Adverse reactions to methyldopa with particular reference to hypotension. American Heart Journal 96: 572–579, 1978PubMedCrossRefGoogle Scholar
  75. Lees KR, Reid JL. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clinical Pharmacology and Therapeutics 41: 597–602, 1987PubMedCrossRefGoogle Scholar
  76. Lowenthal DT, Affrime MB, Meyer A, Kim K, Falkner B, et al. Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function. Chest 83S: 386S–390S, 1983Google Scholar
  77. Lowenthal DT, Matzek KM, Macgregor TR. Clinical pharmacokinetics of clonidine. Clinical Pharmacokinetics 14: 287–310, 1988PubMedCrossRefGoogle Scholar
  78. Ludden TM, McNay JL, Shepherd AMM, Lin MS. Variability of plasma hydralazine concentrations in male hypertensive patients. Arthritis and Rheumatism 24: 987–993, 1981PubMedCrossRefGoogle Scholar
  79. Ludden TM, Shepherd AMM, McNay JL, Lin MS. Hydralazine kinetics in hypertensive patients after intravenous administration. Clinical Pharmacology and Therapeutics 28: 736–742, 1980PubMedCrossRefGoogle Scholar
  80. Luther RR. Terazosin: the new antihypertensive agents with favourable effects on lipids. International Journal of Clinical Pharmacology, Therapy and Toxicology 27: 313–319, 1989Google Scholar
  81. McMahon FG. The centrally acting alpha 2 agonists. In Management of essential hypertension: the new low-dose era, pp. 215–267, Futura, Mount Kisco, 1984Google Scholar
  82. McNeil JJ, Drummer OH, Conway EL, Workman BS, Louis WJ. Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin. Journal of Cardiovascular Pharmacology 10: 168–175, 1987PubMedCrossRefGoogle Scholar
  83. Meacham RH, Emmett M, Kyriakopoulos AA, Chiang ST, Ruelius HW, et al. Disposition of (14)C-guanabenz in patients with essential hypertension. Clinical Pharmacology and Therapeutics 27: 44–52, 1980PubMedCrossRefGoogle Scholar
  84. Messerli FH, Frohlich ED, Suarez DH, Reism E, Dreslinski GR, et al. Borderline hypertension: relationship between age, hemodynamics and circulating catecholamine. Circulation 64: 760–764, 1981PubMedCrossRefGoogle Scholar
  85. Messerli FH, Sundgaard-Riise K, Ventura HO, Dunn FG, Glade LB, et al. Essential hypertension in the elderly: hemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 2: 983–986, 1983PubMedCrossRefGoogle Scholar
  86. Morselli PL, Rovei V, Mitchard M, Durand A, Gomeni R, et al. Pharmacokinetics and metabolism of diltiazem in man (observations on healthy volunteers and angina pectoris patients). In Bing RJ (Ed.) Drug therapy with a new calcium antagonist: diltiazem, pp. 152–167, Hakone Symposium, Excerpta Medica, Amsterdam, 1979Google Scholar
  87. Muhlberg W, Spahn H, Platt D, Mutschler E, Young R. Pharmacokinetics of triamterene in geriatric patients: influence of piretanide and hydrochlorothiazide. Archives of Gerontology and Geriatrics 8: 73–85, 1989PubMedCrossRefGoogle Scholar
  88. Mulinari R, Gavras I, Gavras H. Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. Clinical Therapeutics 9: 678–689, 1987PubMedGoogle Scholar
  89. Mulrow JP, Crawford MH. Clinical pharmacokinetics in therapeutic use of hydralazine in congestive heart failure. Clinical Pharmacokinetics 16: 86–99, 1989PubMedCrossRefGoogle Scholar
  90. Myhre E, Rugstad HE, Hansen T. Clinical pharmacokinetics of methyldopa. Clinical Pharmacokinetics 7: 221–233, 1982aPubMedCrossRefGoogle Scholar
  91. Myhre E, Stenbaek O, Rugstag HE, Arnold E, Hansen T. Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients. Scandinavian Journal of Urology and Nephrology 16: 257–263, 1982bPubMedCrossRefGoogle Scholar
  92. Niemeyer C, Hasenfub G, Wais U, Knauf H, Schafer-Korting M, et al. Pharmacokinetics of hydrochlorothiazide in relation to renal function. European Journal of Clinical Pharmacology 24: 661–665, 1983PubMedCrossRefGoogle Scholar
  93. North RH, Lassman MN, Tan SY, Fernandez-Cruz A, Mulrow PJ. Age and the renin-aldosterone system. Archives of Internal Medicine 137: 1414–1417, 1977CrossRefGoogle Scholar
  94. Pan HY, Hoffman BB, Pershe RA, Blaschke TF. Decline in beta adrenergic receptor-mediated vascular relaxation with aging in man. Journal of Pharmacology and Experimental Therapeutics 239: 802–807, 1986PubMedGoogle Scholar
  95. Persson I. Treatment of hypertension in the elderly with pindolol and clopamide. Journal of the American Geriatrics Society 26: 337–340, 1978PubMedGoogle Scholar
  96. Piepho RW. Individualization of calcium entry-blocker dosage for systemic hypertension. American Journal of Cardiology 56: 105H–111H, 1985PubMedCrossRefGoogle Scholar
  97. Piepho RW, Culbertson VA, Rhodes RS. Drug interactions with the calcium entry blockers. Circulation 75 (Suppl. V): V181–V194, 1987PubMedGoogle Scholar
  98. Quarterman CP, Kendall MJ, Jack DB. The effect of age on the pharmacokinetics of metoprolol and its metabolites. British Journal of Clinical Pharmacology 11: 287–294, 1981PubMedCrossRefGoogle Scholar
  99. Ray WA, Griffin MR, Downey W, Melton LJ. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1: 687–690, 1989PubMedCrossRefGoogle Scholar
  100. Regardh CG. Pharmacokinetic aspects of some beta adrenoceptor blocking drugs. Acta Medica Scandinavica (Suppl. 665): 49–60, 1982Google Scholar
  101. Riddell JG, Harron DWG, Shanks RG. Clinical pharmacokinetics of β-adrenoceptor antagonists: an update. Clinical Pharmacokinetics 12: 305–320, 1987PubMedCrossRefGoogle Scholar
  102. Rigby JW, Scott AK, Hawksworth GM, Petrie JC. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. British Journal of Clinical Pharmacology 20: 327–331, 1985PubMedCrossRefGoogle Scholar
  103. Rikans LE. Drugs and nutrition in old age. Life Sciences 39: 1027–1036, 1986PubMedCrossRefGoogle Scholar
  104. Robertson DRC, Waller DG, Renwick AG, George CF. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. British Journal of Clinical Pharmacology 25: 297–305, 1988PubMedCrossRefGoogle Scholar
  105. Rocci ML, Vlasses PH, Cressman MD, Sirgo MA, Plachetka J. Pharmacodynamics and disposition of labetolol in elderly vs young hypertensives. Abstract. Clinical Pharmacology and Therapeutics 41: 171, 1987Google Scholar
  106. Rocci ML, Vlasses PH, Cressman MD, Sirgo MA, Plachetka JR. Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple dosages. Pharmacotherapy 10(2): 92–99, 1990PubMedGoogle Scholar
  107. Roe DA. Drug-nutrient interactions in the elderly. Geriatrics 41: 57–74, 1986PubMedGoogle Scholar
  108. Roskos KV, Guy RH, Maibach HI. Percutaneous absorption in the aged. Dermatologic Clinics 4: 455–465, 1986PubMedGoogle Scholar
  109. Roux A, Henry JF, Fouache Y, Chau NP, Hervy MP, et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology 29: 202–208, 1983PubMedCrossRefGoogle Scholar
  110. Rowe JW, Troen BR. Sympathetic nervous system and aging in man. Endocrinology Reviews 1: 167–179, 1980CrossRefGoogle Scholar
  111. Rubin PC, Scott PJW, Reid JL. Prazosin disposition in young and elderly subjects. British Journal of Clinical Pharmacology 12: 401–404, 1981PubMedCrossRefGoogle Scholar
  112. Sabanathan K, Castleden CM, Adam HK, Ryan J, Fitzsimons TJ. A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly hypertensive patients. European Journal of Clinical Pharmacology 32: 53–60, 1987PubMedCrossRefGoogle Scholar
  113. Salathe B, Kerle FH. Pharmakokinetik Von Pindolol dei einer gruppe alterer hypertoniker. Aktuel Gerontologie 10(10): 443–447, 1980Google Scholar
  114. Schmucker BL. Aging and drug disposition: an update. Pharmacological Reviews 37: 133–148, 1985PubMedGoogle Scholar
  115. Schwartz JB, Abernethy DR. Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension. American Journal of Cardiolgy 59: 1111–1117, 1987CrossRefGoogle Scholar
  116. Schwartz JB, Keefe DL, Kirsten E, Kates RE, Harrison DC. Prolongation of verapamil elimination kinetics during chronic oral administration. American Heart Journal 104: 198–203, 1982PubMedCrossRefGoogle Scholar
  117. Scott M, Castleden CM, Adam HK, Smith RP, Fitzsimons TJ. The effect of ageing on the disposition of nifedipine and atenolol. British Journal of Clinical Pharmacology 25: 289–296, 1988PubMedCrossRefGoogle Scholar
  118. Sennello LT, Sonders RC, Glassman HN, Jordan DC, Luther RR, et al. Effect of the age on the pharmacokinetics of orally and intravenously administered terazosin. Clinical Therapeutics 10: 600–607, 1988PubMedGoogle Scholar
  119. Shepherd AMM, Irvine NA, Ludden TM, Lin MS, McNay JL. Effect of oral dosage size on hydralazine kinetics and vasodepressor response. Clinical Pharmacology and Therapeutics 36: 595–600, 1984PubMedCrossRefGoogle Scholar
  120. Shepherd AMM, McNay JL, Ludden TM, Lin MS, Musgrave GE. Plasma concentration and acetylator phenotype determined response to oral hydralazine. Hypertension 3: 580–585, 1981PubMedCrossRefGoogle Scholar
  121. Sherlock S, Beam AG, Billing BH, Paterson JCS. Splanchnic blood flow in man by the bromosulfalein method: the relation of peripheral plasma bromosulfalein level to the calculated flow. Journal of Laboratory and Clinical Medicine 35: 923–932, 1950PubMedGoogle Scholar
  122. Sirgo MA, Boyd BK, Applegate WB. Treatment of hypertension in the elderly with labetolol. Pharmacotherapy 9: 295–302, 1989PubMedGoogle Scholar
  123. Smith WE, Steele TH. Avoiding diuretic-related complications in older patients. Geriatrics 38: 117–124, 1983PubMedGoogle Scholar
  124. Somogyi A, Hewson D, Muirhead M, Bochner F. Amiloride disposition in geriatric patients: importance of renal function. British Journal of Pharmacology 29: 1–8, 1990Google Scholar
  125. Stenbaek T, Myhre E, Brodwall EK, Hansen T. Hypotensive effect of methyldopa in renal failure associated with hypertension. Acta Medica Scandinavica 191: 333–337, 1971Google Scholar
  126. Stokes GS. Age-related effects of antihypertensive therapy with alpha-blockers. Journal of Cardiovascular Pharmacology 12 (Suppl. 8): S109–S115, 1988PubMedGoogle Scholar
  127. Storstein L, Larsen A, Midtbo K, Soevareid L. Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. Acta Medica Scandinavica (Suppl. 681): 25–30, 1984Google Scholar
  128. Thananopavarn C, Golub MS, Sambhi MP. Clonidine in the elderly hypertensive: monotherapy and therapy with a diuretic. Chest 83: 410S–411S, 1983Google Scholar
  129. Thomson AH, Whiting B. Population pharmacokinetics of lisinopril in hypertensive patients. Gerontology 33 (Suppl. 1): 17–23, 1987PubMedCrossRefGoogle Scholar
  130. Toth PD, Demeter RJ, Woods JR, Nyhuis AW, Judy WV. Comparison of the effects of pindolol and atenolol on hemodynamic function in systemic hypertension. American Journal of Cardiology 62: 413–418, 1988PubMedCrossRefGoogle Scholar
  131. van Harten J, Burggraf J, Ligthart GJ, van Brummelen P, Breimer DD. Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged and the elderly. Clinical Pharmacology and Therapeutics 45: 600–607, 1989PubMedCrossRefGoogle Scholar
  132. Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR. Effect of age and cigarette smoking on the disposition of propranolol in man. Clinical Pharmacology and Therapeutics 26: 8–15, 1979PubMedGoogle Scholar
  133. Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM. Thiazide effect on the mineral content of bone. New England Journal of Medicine 309: 344–347, 1983PubMedCrossRefGoogle Scholar
  134. Whitehead EM, Walters GE, Williams PEO, Johnston GD. Pharmacokinetics of cilazaprilat in healthy volunteers. British Journal of Clinical Pharmacology 26: 239P–240P, 1988Google Scholar
  135. Williams PEO, Brown AN, Rajaguru S, Walters GE, McEwen J, et al. A pharmacokinetic study of cilazapril in elderly and young volunteers. British Journal of Clinical Pharmacology 27: 211S–215S, 1989PubMedCrossRefGoogle Scholar
  136. Williams RL, Thornhill MD, Upton RA, Blume C, Clark TS, et al. Absorption and disposition of two combined formulations of hydrochlorothiazide and triamterene: influence of age in renal function. Clinical Pharmacology and Therapeutics 40: 226–232, 1986PubMedCrossRefGoogle Scholar
  137. Wing LMH, Reid JL, Davies DS, Neill EAM, Tippetat P, et al. Pharmacokinetic and concentration effect relationships of clonidine in essential hypertension. European Journal of Clinical Pharmacology 12: 463–469, 1977PubMedCrossRefGoogle Scholar
  138. Wood AJJ, Vestal R, Spannuth CL, Stone WJ, Wilkinson GR, et al. Propranolol in renal failure. British Journal of Clinical Pharmacology 10: 561–566, 1980PubMedCrossRefGoogle Scholar
  139. Working Group on Hypertension in the Elderly. Statement on hypertension in the elderly. Journal of the American Medical Association 256: 70–74, 1986CrossRefGoogle Scholar
  140. Zatuchni J. Verapamil-digoxin interaction. American Heart Journal 108: 412–413, 1984PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Robert W. Piepho
    • 1
  • Kermit J. Fendler
    • 1
  1. 1.Divisions of Pharmacology and Pharmacy PracticeUniversity of Missouri-Kansas City, School of PharmacyKansas CityUSA
  2. 2.University of Missouri-Kansas City, School of PharmacyKansas CityUSA

Personalised recommendations